BioVie (BIVI) Research Hub

BioVie (BIVI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.33 USD (+7.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.91, market cap 0.01B. This hub links to the full technical, earnings and options research available for BIVI.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close1.33 USD (+7.26%)
52-week range0.82 USD – 2.48 USD
Trend regimeRange
14-day RSI44.9 (Bearish)
Trailing P/E-0.91
Market cap0.01B
Dividend yield0.00%
Next earnings2026-09-02

Available research for BIVI

Earnings

BIVI earnings date and last-quarter result: next report 2026-09-02, last quarter beat, P/E -0.91. Updated 2026-07-23.

Options: Covered Call

Covered Call on BIVI: how it works, illustrative setup around the real 1.33 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on BIVI: how it works, illustrative setup around the real 1.33 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on BIVI: how it works, illustrative setup around the real 1.33 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

BIVI technical analysis: range, last 1.33 USD, RSI 44.9, 52w range 0.82 USD–2.48 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is BIVI in?

BioVie (BIVI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is BIVI in an uptrend or downtrend?

As of 2026-10-26, BIVI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is BIVI's trailing P/E ratio?

BIVI's trailing P/E is -0.91, with a market cap of 0.01B. See the earnings research page for full valuation detail.

When does BIVI next report earnings?

BIVI is next scheduled to report earnings on 2026-09-02.